Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults. Given in combination at full doses, with or without dacarbazine, these agents have induced higher response rates than were obtained with single-agent therapy. Because they involve considerable myelotoxicity, however, full-dose regimens should be reserved for patients with good performance status and without potential septic foci. Obviously, higher response rates do not automatically translate into improved survival. In soft tissue sarcomas, full-dose polychemotherapy will most probably provide a survival benefit only in selected patients in whom surgery can be performed in combination with chemotherapy. Prospective trials in such patients, although difficult to carry out, would be highly desirable. The information they would provide might help the clinician tail or treatment in a more rational way and improve chances of cure or long-term survival in at least some patient subgroups.
|Journal||Cancer Chemotherapy and Pharmacology|
|Issue number||SUPPL. 2|
|Publication status||Published - 1993|
ASJC Scopus subject areas
- Cancer Research